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Cancer development involves changes driven by the 
 epigenetic machinery, including nucleosome position-
ing. Recently, the concept that adenoviral replication 
may be driven by tumor specific promoters (TSPs) 
gained support, and several conditionally replicative 
adenoviruses (CRAd) exhibited therapeutic efficacy in 
clinical trials. Here, we show for the first time that plac-
ing a nucleosome positioning sequence (NPS) upstream 
of a TSP combined with Wnt-responsive motifs (pART 
enhancer) enhanced the TSP transcriptional activity and 
increased the lytic activity of a CRAd. pART enhanced 
the transcriptional activity of the gastrointestinal cancer 
(GIC)-specific REG1A promoter (REG1A-pr); moreover, 
pART also increased the in vitro lytic activity of a CRAd 
whose replication was driven by REG1A-Pr. The pART 
enhancer effect in vitro and in vivo was strictly dependent 
on the presence of the NPS. Indeed, deletion of the NPS 
was strongly deleterious for the in vivo antitumor efficacy 
of the CRAd on orthotopically established pancreatic 
xenografts. pART also enhanced the specific activity of 
other heterologous promoters; moreover, the NPS was 
also able to enhance the responsiveness of hypoxia- and 
NFκB-response elements. We conclude that NPS could 
be useful for gene therapy approaches in cancer as well 
as other diseases.
Received 4 December 2012; accepted 10 April 2013; advance online  
publication 28 May 2013. doi:10.1038/mt.2013.93
INTRODUCTION
Cancer is the second leading cause of death in the developed 
world,1,2 and gastrointestinal cancers (GICs) are among the most 
frequently occurring cancers worldwide.3 Gastric cancer is the 
fourth most common cancer among GICs worldwide, account-
ing for >10% of cancer-related deaths. In most cases, patients are 
diagnosed at an advanced stage of the disease and have an esti-
mated 5-year survival rate of <20%.1,2,4 Pancreatic cancer ranks as 
the fourth and fifth common cancer in men and women, respec-
tively, and has the lowest 5-year survival rate of any GIC. Due to 
the absence of effective screening methods, pancreatic cancer is 
often diagnosed at advanced stages.5 Finally, colorectal cancer is 
the third most common cancer globally and has the fourth high-
est mortality rate, accounting for almost 8% of all cancer-related 
deaths.2–4
Despite advances in the use of diagnostic imaging, such as 
endoscopy or colonoscopy for improved early detection, certain 
GICs, such as pancreatic and gastric cancers, and advanced stages 
of colon cancer are not amenable to current mainstay treatments.6 
Personalized medicine has improved the response in patients with 
advanced colorectal cancer treated with the EGFR-targeted anti-
body cetuximab and in gastric cancer patients expressing the erbB 
receptor treated with trastuzumab.7 However, only a small per-
centage of patients with gastric and colorectal cancers can benefit 
from novel therapies, and in all cases, the benefit is mainly tran-
sient due to tumor heterogeneity. In pancreatic cancer, standard 
and novel therapies have failed to attenuate disease aggressiveness 
or confer improvements in survival.6 Thus, novel therapies are 
urgently needed.
Adenovirus-based virotherapy appears as a novel approach 
for the treatment of different types of cancer including those of 
gastrointestinal origin.8 These oncolytic adenoviruses have been 
introduced to target GICs, and a few have been rapidly translated 
to the clinic, where their safety has been clearly demonstrated.9 
However, despite their promise in preclinical trials and the safety 
observed in humans, oncolytic adenoviruses have shown limited 
efficacy in clinical trials thus far.9,10 For instance, ONYX-15, a 
naturally occurring E1B-deleted replicating oncolytic adenovirus, 
has been used in clinical trials for advanced colorectal cancer,11 
GICs metastatic to the liver12 and locally advanced pancreatic 
 cancer13,14 with modest results.
More recent approaches introduced the concept of condition-
ally replicative adenoviruses CRAds where the transcriptional reg-
ulation of E1A expression, which drives viral replication, is under 
the control of a tumor specific promoters (TSPs). These CRAds 
provide a personalized approach because viral activity mostly 
occurs in cells expressing the gene from which the promoter has 
been selected.15 Moreover, targeting specificity can be improved 
by pseudotyping the virus with non-native fibers obtained from 
other viral strains or by genetic modifications that can retarget the 
virus through non-natural receptors.16,17 Although these modified 
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viruses are safe, improvement in therapeutic terms remained low 
due to restricted viral spreading in desmoplastic tumors, and the 
resistance of malignant cells to incorporate a sufficient amount 
of  virus and the low expression levels of the gene regulated by 
the TSP.
Cancer development may result from global changes driven 
by the epigenetic machinery that includes DNA methylation, his-
tone modification, and nucleosome positioning. In eukaryotic 
cells, DNA is packaged in arrays of particles called nucleosomes, 
which correspond to a 147 bp stretch of DNA wrapped around an 
octameric core of histones.18 This structure, which contains ~1.7 
turns of DNA, enforces DNA bending and regulates the binding of 
proteins that act as repressors or activators of gene expression to 
cognate DNA target sites.18 Several reports indicate that modifica-
tions in DNA-histone interactions and the recruitment of chroma-
tin remodeling complexes alter and displace nucleosomes, thereby 
modifying the structure of chromatin and allowing or inhibiting 
gene transcription.19–22 We showed that a tissue regulatory ele-
ment located within the proximal region of the osteocalcin gene 
promoter is a recognition site for the heterodimer CBFα/AML/
PEBP2α.20,21 A novel 182 bp nucleosome positioning sequence 
(NPS) in the osteocalcin promoter is responsible for positioning a 
nucleosome upstream of the CBFα binding site, leaving this ele-
ment partially exposed and providing a spatial organization of the 
promoter that allows functional interactions between distally and 
proximally bound promoter elements.20,21
One of the strategies to boost the activity of promoters with 
invariably low transcriptional capacity is to add motifs responsive 
either to tumor microenvironmental conditions or to deregulated, 
constitutively active intracellular pathways. One of the paradigms 
for the latter in GICs is the Wnt/β-catenin signal transduction 
cascade.23,24 Mutations in the genes encoding the Wnt signal-
ing components APC, axin and β-catenin occurs in 30–70% of 
GICs, leading to the activation of Wnt-dependent target genes.23–25 
Only a few reports have studied the effect of TCF/LEF responsive 
sequences as heterologous enhancers to augment the transcrip-
tional activity of a given promoter.26–29 We have previously char-
acterized the promoter region of the COX-2 gene and identified 
a 0.8 kb Wnt/β-catenin responsive region demonstrating high 
transcriptional activity.30 This region contains a novel TCF/LEF 
response element (TBE site-II) that directly responds to Wnt/β-
catenin signaling. We hypothesized that a chimeric enhancer 
Figure 1 REG1A promoter activity. (a) Quantitative determination of REG1A mRNA expression by qPCR. β-actin was used as an internal control. 
(b) Schematic representation of REG1A promoter variants. (c,d) Cells were transiently transfected with 100 ng of the different constructs and assessed 
for luciferase activity. Cells were cotransfected with 1 ng of PRL-SV40 Renilla as an internal control. Promoter activity was normalized as the ratio 
between firefly luciferase and Renilla and expressed as the fold induction over empty vector. Each figure represents at least three independent experi-
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sequence comprising Wnt-responsive elements combined with 
the NPS of the osteocalcin promoter might improve the transcrip-
tional activity of GIC-specific promoters. Here, we demonstrate 
that a chimeric sequence named pART, which is composed of four 
tandemly repeated COX-2 TBE site-II elements cloned upstream 
of the osteocalcin NPS signal, enhanced the activity of the human 
REG1A gene promoter, driving the replication and lytic capacity 
of a conditionally replicative adenoviruses (CRAd). Importantly, 
the in vitro and in vivo activity of the CRAd was strictly depen-
dent of the presence of the NPS because deletion of this sequence 
abolished the enhancer effect of pART. Moreover, the NPS also 
enhanced the responsiveness of additional responsive elements.
RESULTS
Design and assessment of the enhancer activity of 
the hybrid artificial enhancer pART
To take advantage of the specific structural features of the nucleo-
somes placed between regulatory elements,20 we designed the 
 chimeric enhancer pART by placing four tandemly repeated cop-
ies of the TCF/LEF-responsive element (TBE) from the human 
COX-2  gene promoter (−692 bp to −683 bp)30 upstream of the NPS 
from the rat osteocalcin gene promoter (−286 bp to −106 bp).21 
The transcriptional capacity of pART was initially assessed by 
cloning downstream a specific fragment from the human REG1A 
gene, which has been described to be differentially expressed in 
gastric, pancreatic and colon cancer compared with adjacent non-
malignant tissue.31–33
REG1A mRNA was expressed at high levels in AGS and 
MKN45 gastric cancer cell lines and SW1990 pancreatic cancer 
cells; HT29 and Lovo colorectal cancer cells expressed moder-
ate levels of REG1A mRNA, whereas N87 gastric cancer cells 
did not exhibit significant expression of this gene (Figure 1a 
and Supplementary Figure S1). WI38 human fetal lung fibro-
blasts and A549 human lung carcinoma cells that were used as 
non-GIC control cells did not express detectable levels of REG1A 
(Figure 1a and Supplementary Figure S1).
We next cloned a 1.0 kb fragment of the human REG1A  gene 
promoter (extending from −947 bp to +75 bp) that includes, 
among other elements, a non-functional TBE motif (data not 
shown) and a TATA box sequence (Supplementary Figure S1b). 
The 1.0 kb REG1A promoter fragment (pREG1A-947) and shorter 
versions of this fragment (Figure 1b) were placed upstream of 
the luciferase reporter gene. The 1.0 kb fragment was unable to 
drive significant luciferase activity when transiently transfected 
into the REG1A mRNA-positive MKN45 and AGS gastric can-
cer cells (Figure 1c). However, the deletion of 0.1 kb from the 
5′-end (pREG1A-859-Luc) and the deletion of 0.4 kb from the 
5′-end (pREG1A-571-Luc) in particular induced strong REG1A 
promoter activity in MKN45 and AGS gastric cancer cells com-
pared with the other promoter fragments (Figure 1c). A further 
0.7 kb deletion (pREG1A-293-Luc) resulted in a significant reduc-
tion in the promoter activity (Figure 1c), suggesting that the 
−571/−293 fragment contains the key regulatory elements that 
activate REG1A gene transcription. REG1A promoter activity 
was extremely low in N87 gastric cancer cells, which is consistent 
with the low levels of REG1A mRNA expression in this cell line 
(Figure 1c). As expected, none of the promoter fragments showed 
any activity in REG1A-negative WI38 fibroblasts. The lack of 
REG1A promoter activity in WI38 cells was not due to reduced 
transfection efficiency because other transiently transfected pro-
moter-reporter constructs, such as the p21 gene promoter, exhib-
ited high levels of transcriptional activity (Figure 1d), confirming 
that REG1A promoter activity specifically occurs in cells express-
ing REG1A mRNA.
Figure 2 Enhancement of the REG1A promoter activity by the NPS and 
Wnt-responsive elements. (a) Schematic representation of the different 
constructs. (b) Gene reporter assays to assess the role of the NPS. Cells 
were transiently transfected with different constructs with or without pART 
and the NPS and assessed for luciferase activity. (c) Cells were transiently 
transfected with the different constructs and cotransfected with or without 
a dominant-negative mutant (DN-TCF) of the TCF/LEF transcription fac-
tor. (d) Gene reporter assays in HEK-293 cells transfected with the different 
constructs in the presence or absence of a construct expressing β-catenin. 
SuperTOPFLASH (STF) promoter was used as a control for β-catenin activity. 
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On the basis of the previous data, we decided to place REG1A-
571 downstream of the pART synthetic enhancer to generate 
pART-REG (Figure 2a). The transient transfection of pART-REG 
in MKN45 and AGS gastric cancer cells led to significantly higher 
(~2-fold) luciferase activity compared with REG-571 (Figure 2b). 
This enhanced promoter activity was strictly dependent on the 
NPS because pART∆NPS, which lacks the NPS, exhibited tran-
scriptional activity equivalent to that shown by REG-571 (Figure 
2b). Importantly, pART had no effect on the transcriptional 
activity of REG1A in REG1A-negative WI38 fibroblasts and 
human embryonic kidney HEK-293 cells (Figure 2d), indicating 
that pART-enhanced REG1A activity exclusively in cells where 
the promoter is already active. Moreover, the NPS showed no 
enhancer activity itself (data not shown).
We next determined whether the Wnt/β-catenin responsive-
ness contributes to the enhanced activity exerted by pART. pART-
REG activity was reduced by almost 50% upon coexpression of 
the dominant-negative mutant DN-TCF, indicating that the Wnt/
β-catenin responsive elements participate in the enhancement of 
the REG1A activity induced by pART (Figure 2c). As a control, 
Figure 3 In vitro lytic activity of the CRAd carrying pART. (a) Schematic representation of the CRAds constructs. (b) Cells were exposed to  different 
multiplicity of infections for 6 days followed by the assessment of cell viability with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 
2-(4-sulfophenyl)-2H-tetrazolium (MTS). (c) Similar to the previous panel. Each figure represents at least three independent experiments. Statistical 
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we observed that enforced expression of DN-TCF also inhibited 
SuperTOPFLASH reporter activity (Supplementary Figure S2). 
Notably, DN-TCF did not affect pART∆NPS-REG activity (Figure 
2c), indicating that the TBE sites contribute to pART-REG-571 
activity only when the NPS sequence is present (Figure 2d). Taken 
together, these results indicate that the transcriptional activity of 
pART-REG requires the presence of the NPS, which facilitate a 
functional interaction between the REG-571 promoter and the 
distal tandem repeat in Wnt/β-catenin responsive elements.
pART enhances the lytic capacity of an oncolytic 
adenovirus
We next evaluated the ability of pART-REG to drive the lytic activity 
of a CRAd pseudotyped with a 5/3 fiber. For this  purpose, we cloned 
pART-REG in front of the early adenoviral gene E1A to obtain 
AdpART(REG) (Figure 3a). To further  confirm the contribution of 
pART and the NPS to the lytic activity of AdpART(REG), we con-
structed an AdREG that lacks pART and an AdpART(REG)∆NPS 
that lacks the NPS and the non- replicative virus AdpART(REG)
LUC (Figure 3a). The in vitro lytic capacity of AdpART(REG) was 
evaluated in REG1A mRNA-positive cells (AGS, MKN45, SW1990, 
HT29, and LoVo) and REG1A mRNA-negative A549 lung cancer 
cells and WI38 fibroblasts. AdpART(REG) exhibited the highest 
lytic activity on AGS gastric cancer cells (at 10 multiplicity of infec-
tion), which is consistent with the highest REG1A mRNA levels 
expressed by this cell line (Figure 3b). Significant lytic activity was 
also observed on MKN45 gastric and HT29 colon cancer cells, 
whereas LoVo colon and SW1990 pancreatic cancer cells were 
more resistant to the CRAd lytic activity (Figure 3b), which is 
likely due in part to the less efficient infectivity of these cells by the 
5/3 pseudotyped virus (Supplementary Figure S3). As expected, 
an almost complete absence of lytic activity for AdpART(REG) was 
observed on REG1A mRNA-negative N87, A549 and WI38 cells 
(Figure 3b). Thus, AdpART(REG) showed attenuated but highly 
specific activity compared with AdE1A-wt (Figure 3b). In agree-
ment with the results using transiently transfected constructs, the 
cytopathic activity of AdpART(REG) was strongly dependent on 
the presence of the NPS. Indeed, removal of the NPS led to a great 
reduction in the lytic activity of AdpART(REG) on gastric and 
pancreatic cancer cells (Figure 3c).
To establish whether the pART effect is associated with the 
enhancement of viral E1A expression levels, we transduced 
REG1A-positive cells with AdpART(REG) and AdREG. Cell 
extracts were obtained at different time points post-infection to 
evaluate E1A expression by quantitative real-time PCR (qRT-
PCR) and western blot. E1A mRNA expression was detectable 2 
hours after infection with AdpART(REG) (Figure 4a,b) but only 
8–24 hours after infection with AdREG (Figure 4a,b). Consistent 
with this result, the E1A protein was detected only after 8 hours, 
following infection with AdpART(REG), whereas it was almost 
undetectable after infection with AdREG (Figure 4c). As a control, 
we observed no E1A mRNA expression following the infection 
of REG1A-negative A549 lung cancer cells with AdpART(REG), 
whereas the wild type virus induced E1A mRNA expression 
immediately after 2 hours (Supplementary Figure S4). Taken 
together, these data suggest that pART is a potent enhancer of the 
transcriptional activity of the REG1A promoter, increasing the 
lytic activity of AdpART(REG) by stimulating E1A transcription 
and hence viral replication.
In vivo analysis of the therapeutic potential of the 
CRAd carrying pART
Once the in vitro lytic capacity of AdpART(REG) was confirmed, 
we proceeded to study its in vivo therapeutic efficacy. In pre-
liminary studies, we xenografted SW1990 pancreatic cancer cells 
s.c. in male nude mice. When tumors reached an average size of 
100 mm3, the mice were administered three doses of either 1 × 108 
viral particles of AdpART(REG) or vehicle. The administration 
of AdpART(REG) significantly reduced the in vivo growth of 
SW1990 tumors in 4/5 animals (Figure 5a). In only one case, a 
mouse that received AdpART(REG) developed a tumor at a size 
comparable with that observed in the control group (Figure 5a).
To further confirm the therapeutic efficacy of AdpART(REG) 
and the role of the NPS, we orthotopically xenografted SW1990-
mcherry-LUC cells in mouse pancreases. Mice harboring 
10-day-old established tumors were split in four groups and 
administered i.p. with one dose of 1 × 109 vp of AdpART(REG), 
AdpART(REG)∆NPS, AdREG, or AdpART(REG)LUC. Mice 
were followed in real time with a bioluminometer and killed 
30 days after viral administration. Following assessment 
at necropsy (Figure 5b), we observed that only the group 
of mice treated with AdpART(REG) showed a statistically 
 significant reduction in tumor volume and weight compared 
with the control mice (Figure 5c). Tumors in mice injected 
with AdREG or AdpART(REG)∆NPS showed no significant 
Figure 4 Enhancement of E1A expression by pART. (a) E1A mRNA 
expression in cells exposed to 100 multiplicity of infection (MOI) of the 
different viruses. HPRT mRNA levels were used as an internal control. 
(b) Quantification of the data in a in arbitrary units of E1A relative to the 
HPRT levels. (c) Western analysis of E1A expression using β-actin (actin) 
as an internal control. Each figure represents at least three independent 
experiments. Statistical significance was determined using analysis of 
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difference compared with the control (Figure 5c), demonstrat-
ing that either the absence of pART or the deletion of the NPS 
strongly reduced the antitumor efficacy of the CRAd. Although 
AdpART(REG)∆NPS and AdREG were unable to significantly 
inhibit tumor growth as a whole, we observed a clear antitumor 
effect in one to two mice (see Figure 5c and the comparison of 
the two mice treated with AdpART(REG)ΔNPS in Figure 5d), 
suggesting that these CRAds might exhibit a partial antitumor 
activity that is enhanced when the virus included pART.
pART enhances the transcriptional activity of 
additional TSPs
To establish whether pART can enhance the transcriptional 
activity of additional heterologous promoters, we prepared a 
Figure 5 AdpART-REG-E1A effect on the in vivo growth of human pancreatic cancer xenografts. (a) S.c. growth of SW1990 cells in nude 
mice treated with AdpART(REG) or vehicle. Each line represents a single mouse. The arrows indicate the time of viral (or vehicle) administration. 
(b) Representative macroscopic images of orthotopic pancreatic tumors 30 days after viral administration. (c) The tumor volumes and weights 
 corresponding to mice treated with the different viruses. All measurements were obtained with double blind measurement. Statistical significance 
was determined using analysis of variance (*P < 0.05). (d) Representative whole-body images of bioluminescence activity of mice harboring SW1990 
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non-replicative adenovirus by subcloning pART upstream of 
the human colon cancer-specific A33 TSP to drive luciferase 
expression.34 We observed more than a two-, four-, and eightfold 
increase in the transcriptional activity of pART-A33 in REG1A-
positive LoVo, AGS, and SW1990 malignant cells, respectively, 
compared with the A33 promoter alone (Figure 6a). No pART 
enhancement was observed in the REG1A-negative A549 lung 
cancer and A375 melanoma cells (Figure 6a). Consistent with 
the results obtained with the REG1A and A33 promoter, pART 
also induced a 10-fold increase in the transcriptional activity of a 
0.4 kb cdc25b gene promoter sequence (Weber et al., manuscript 
submitted) in cdc25b-positive SW1990 pancreatic cancer cells 
(Figure 6b). A slight, but non-statistically significant increase was 
also observed in the cdc25b-negative skin fibroblasts CCD1140Sk 
(Figure 6b). pART enhancement was consistent with the nuclear 
levels of β-catenin in the different cell lines because the largest 
enhancement was observed in SW1990 cells that exhibited the 
highest β-catenin expression levels (Supplementary Figure S5).
NPS enhanced the responsiveness of hypoxia- and 
NFκB-responsive elements
To further establish the capacity of the NPS to enhance the activ-
ity of additional responsive sequences, we replaced the Wnt-β-
catenin responsive elements in pART with hypoxia (HRE)- and 
NFκB (NF-RE)-responsive elements35 upstream of the REG1A 
promoter to drive luciferase expression. The transient transfec-
tion of REG1A-positive AGS and LoVo malignant cells with the 
expression constructs showed a dramatic enhancement in the 
activity of the chimeric promoters containing either an HRE or 
NF-RE (Figure 7). Moreover, HRE activation occurred only under 
hypoxia but not under normoxia (Supplementary Figure S6). 
HRE and NF-RE enhancement was strictly dependent on the NPS 
because its removal from the constructs abrogated the enhanced 
transcriptional activity (Figure 7). In addition, the constructs 
containing the NPS and the responsive elements were unable to 
induce a significant change in the REG1A promoter activity in 
A549 and A375 cells lacking REG1A expression (Figure 7), stress-
ing the high stringency of the synthetic enhancers.
DISCUSSION
DNA promoter regions determine the initiation rates of transcrip-
tion by acting as anchoring platforms for the RNA polymerase II 
complex.36 These sequences interact with cell specific transcrip-
tional microenvironments, altering the chromatin structure and 
hence regulating gene expression.37 On the basis of these well-
established general concepts of transcriptional regulation, we 
designed an artificial chimeric enhancer, pART, which contains 
four Wnt-responsive elements positioned upstream of a NPS. 
pART proved to be effective in increasing the transcriptional 
activity of the REG1A promoter without altering its specificity, 
and it efficiently enhanced the replication and therapeutic efficacy 
of an oncolytic adenovirus.
To validate the enhancer capacity of pART, we selected the 
REG1A gene promoter as a novel TSP. REG1A mRNA is highly 
upregulated in GIC.31–33 We showed that a promoter fragment that 
spans 571 bp is necessary and sufficient to function as a TSP and 
drives the replication of an oncolytic adenovirus. Despite our pre-
vious study of the human COX-2 gene in GIC cells,30 we avoided 
using the COX-2 gene promoter instead of REG1A because 
COX-2 is highly expressed during tissue inflammatory processes, 
raising the potential risk of increasing collateral unwanted effects 
in vivo.38 The recombinant pART/REG1A promoter was active in 
an adenoviral context in different GIC cell lines such as the gastric 
cancer cells MKN45 and AGS, the pancreatic cancer cells SW1990 
and the colon cancer cells LoVo and HT29; the lack of activity in 
WI38 fibroblasts and A549 lung cancer cells indicates that pART/
REG1A can be widely useful in a wide variety of types of GICs. 
Most importantly, AdpART(REG) was also able to strongly inhibit 
the in vivo growth of orthotopic pancreatic tumors following the 
direct intra-tumor administration of the CRAd. Our in vitro data 
confirmed that pART-enhanced E1A transcriptional expression, 
which is reflected by its detection as early as 2 hours after infec-
tion. CRAds lacking pART only produced detectable E1A expres-
sion 8 hours after infection. Although the REG1A promoter 
attenuated viral lytic activity compared with the wild type virus, it 
maintained a high specificity when driving viral replication alone 
or when pART was included in the construct; indeed, the result-
ing CRAd was active only in REG1A-positive cells, whereas the 
wild type virus was highly lytic regardless of REG1A expression.
Different regulatory sequence motifs have been used in the 
past to increase the transcriptional activity of TSPs and enhance 
the potency of oncolytic viruses. Generally, these types of studies 
Figure 6 pART enhancement of the transcriptional activity of 
 additional promoters. Transcriptional activity of non-replicative 
adeno viruses expressing luciferase under the control of the (a) A33 or 
(b) cdc25b promoters. Cell extracts were assayed 48 hours afterward 
for firefly and Renilla luciferase. Data are shown as relative luciferase 
units (RLU) normalized to Renilla. Each column represents the mean 
± SD (n = 3). Statistical significance was determined using the analysis of 
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focused on motifs responsive to the tumor microenvironment 
including hypoxia, inflammation and reactive oxygen species.39,40 
Elements that respond to tissue-specific and constitutively active 
signaling pathways include those responsive to the Wnt/β-catenin 
pathway in GIC cells26–29 and estrogen or androgen responsive 
motifs in breast or prostate cancer, respectively.41,42 Here, we have 
used for the first time a sequence that positions nucleosomes, a 
chromosomal structure that can define spatial features and the 
functional organization of the transcriptional machinery at gene 
promoters. The enhanced activity exerted by pART was highly 
dependent on the presence of the NPS because deletion of this 
region completely obliterated not only the pART enhancer effect 
but also the in vitro and in vivo efficacy of the CRAds. It was 
unexpected that the removal of the 200 bp NPS from pART, which 
brings the Wnt-responsive motifs closer to the transcription ini-
tiation site, would result in the loss of enhancement activity. Thus, 
we suggest that the role of the NPS is to bring the Wnt-responsive 
elements in close spatial proximity to the REG1A promoter regu-
latory elements to enhance promoter activity (Figure 8). A special 
juxtaposition that brings proximal and distal Wnt-responsive sites 
close to the transcription start site has been recently described.43
Both the in vitro and in vivo studies confirmed the strict depen-
dence of viral activity on the presence of the NPS. Interestingly, 
pART was also able to enhance the transcriptional activity of other 
TSPs in an adenoviral context. In addition, pART was also able 
to increase the transcriptional activity of the non-tumor-related, 
neural enolase promoter (Supplementary Figure S7). Finally, 
the presence of the NPS was a sine qua non condition for the 
responsiveness of not only the Wnt-β-catenin-responsive element 
but also the hypoxia- and NFκB-responsive elements. Indeed, 
removal of the NPS completely abrogated the enhanced transcrip-
tional activity induced by the three different responsive elements. 
The incorporation of pART led to significantly improved TSP and 
CRAd activity in vitro and in vivo. On the basis of all of the data 
present in this study, it can be concluded that the use of NPSs 
could be a useful tool for gene therapy approaches in cancer and 
other human diseases as well.
MATERIALS AND METHODS
Cell lines. The human pancreatic cancer cells SW1990, colorectal cancer 
cells LoVo and HT29, gastric cancer cells AGS and N87, lung carcinoma 
cells A549, melanoma cells A375, fetal lung fibroblasts WI38, skin fibro-
blasts CCD1140Sk cells, and human embryonic kidney cells (HEK-293) 
were obtained from the ATCC (American Tissue Culture Collection, 
Rockville, MD). The gastric cancer cells MKN45 (Japanese Collection of 
Research Bioresources, Japan) were generously donated by Andrew Quest 
(University of Chile). All of the cell lines were grown following the manu-
facturer’s recommendations for culture media, supplements and antibiot-
ics in a 37 °C atmosphere containing 5% CO2.
Plasmid vectors. SuperTOPFlash-luciferase, the pRL-SV40 plasmid,30 the 
constitutive active β-catenin (S33Y) β-cat-GOF,44 and the dominant-nega-
tive pDN-TCF4 expression plasmids25 have been previously described. The 
REG1A-947 promoter was obtained by high fidelity PCR amplification 
from human genomic DNA using the following primers: pREG1A-947-
Fwd and pREG1A-Rev (Supplementary Table S1). This DNA fragment 
(positions −947 to +75) was cloned into the pGL3-basic plasmid (Promega, 
Madison, WI). REG1A-859, and REG1A-293 were generated by PCR 
with the pREG1A-859-Fwd, pREG1A-293-Fwd, and pREG1A-Rev prim-
ers (Supplementary Table S1) using the pGL3-REG1A-947 plasmid as a 
template. The REG1A-571 plasmid was obtained from pGL3-REG1A-947 
by cleaving with the HindIII and BglII restriction enzymes (New England 
Biolabs, Ipswich, MA). For pART plasmid construction, an oligonucle-
otide containing a multimerized copy (4X) of the TCF/LEF responsive 
element (TBE) from the COX-2 promoter (site-II)30 was obtained by 
chemical synthesis, and it was introduced into pART with the KpnI and 
XhoI restriction sites (New England Biolabs, Ipswich, MA). The NPS was 
obtained from the rat osteocalcin promoter using high fidelity PCR ampli-
fication with the NPS-Fwd and NPS-Rev specific primers (Supplementary 
Table S1), which contain XhoI and SacI restriction sites. The resulting 
182 bp fragment was linked to the 4XTBE sequence after cleavage at the 
XhoI site (New England Biolabs, Ipswich, MA) and ligated using T4 ligase 
(New England Biolabs, Beverly, MA). Finally, this cassette (4XTBE-NPS) 
was linked to the REG-571 promoter sequence by SacI restriction site 
Figure 7 Enhancer activity of hypoxia- and NFκB-responsive ele-
ments placed upstream of the NPS. (a) Gene reporter assays with 
different constructs containing NFκB- or HRE-responsive elements and 
NPS. (b) Cells were transiently transfected with different constructs 
and assayed for luciferase activity under normoxic or hypoxic (1% O2) 
 conditions. Data are shown as relative luciferase units (RLU) normalized 
to Renilla. Each column represents the mean ± SD (n = 3). Statistical 
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Figure 8 Schematic representation of the potential spatial confor-
mation of Enhancer-NPS-TSP sequences in the nuclear environment.
Enhancer
TSP
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cleavage/ligation (resulting in the 4XTBE-NUC-REG571 sequence) and 
inserted in the pGL3-basic vector in the KpnI and BglII restriction sites 
(New England Biolabs, Ipswich, MA). The pART∆NPS plasmid was gener-
ated by cleavage with the XhoI and SacI restriction enzymes (New England 
Biolabs, Ipswich, MA). The pGL3-NSE promoter was obtained from 
Addgene (plasmid 11606) (Addgene, Cambridge, MA). pGL3-pART-NSE 
was constructed by the insertion of pART into the pGL3-NSE plasmid 
in the NheI/BgllI restriction sites. The pNFκB-NPS-REG and HRE-NPS-
REG constructs were generated from pART-REG-571 by 4xTBE sequence 
cleavage (KpnI/XhoI)and insertion of the NFκB and HRE enhancers35 
into the KpnI/SmaI and KpnI/StuI(Klenow) restriction sites, respectively. 
Successful cloning was confirmed by restriction enzyme digestion analyses 
and automated sequencing.
Adenoviral construction. The pART-REG-571, pART-∆NPS, and REG-
571 promoters were cloned upstream of the E1A or Luciferase (LUC) genes 
into adenoviruses containing the chimeric fiber 5/3.45 The pART-REG-571 
promoter was isolated from the pGL3-pART-571 construct by digestion 
with the KpnI/BglII restriction enzymes (New England Biolabs, Ipswich, 
MA) and subcloning into the pShuttle-1 vector (Stratagene, La Jolla, CA) 
followed by E1A or LUC45 in the XbaI/SalI sites, hence producing pShuttle-
pART(REG)-E1A or pShuttle-pART(REG)-LUC (also pShuttle-REG-E1A 
and pShuttle-∆NPS-E1A). AdpART-A33-LUC and AdpART-CDC25B-
LUC were generated by the subcloning of pART upstream of the A3334 or 
cdc25B (Weber et al., manuscript submitted) gene promoters following the 
methodology described above, resulting in the pShuttle-pART-A33-LUC 
and pShuttle-CDC25B-LUC constructs, respectively. Viral constructs con-
taining the chimeric promoters were prepared using previously available 
backbones and shuttle vectors followed by viral stock production.45
Luciferase reporter assays. Cell lines grown in 24-well plates were trans-
fected using FUGENE 6 (Roche Applied Science, IN) following the manu-
facturer’s indications. Different amounts of the described plasmids were 
assayed for 24 hours. The cells were then collected and assayed for Firefly 
and Renilla Luciferase activities (Promega) using a Genius luminometer 
(TECAN, Maennedorf, Switzerland). Each of these experiments was per-
formed at least three times. For assays using adenoviruses, luciferase assays 
followed Lopez et al.44 The luciferase activity was normalized by the total 
protein concentration in the cell lysate.
In vitro cytotoxicity assay. To determine the virus-mediated cytotoxicity, 
1 × 104 cells were seeded in 24-well tissue culture plates and infected with 
CRAds at the indicated multiplicity of infections. After 6 days, cell viability 
was measured as described.44
mRNA expression. RNA extraction and RT-PCR assays were performed 
as previously reported.30 The mRNA was measured by qRT-PCR in 
an Mx 3005p qPCR thermocycler (Stratagene) using specific primers 
(Supplementary Table S1). PCR conditions were as follows: an initial 
denaturation for 150 seconds at 94 °C followed by 39 cycles of 45 seconds 
at 94 °C, 30 seconds at 60 °C and 30 seconds at 72 °C. All reactions were 
performed in triplicate. In this assay, HTRP gene expression was measured 
as an internal control using the HTRP-Fwd and HTRP-rev specific primers 
(Supplementary Table S1).
Assessment of E1A levels. To determine the E1A mRNA levels, 1.5 × 106 
cells per well were seeded in a six-well plate. The next day, the cells were 
infected with the indicated viruses at a 500 multiplicity of infection. After 
2, 4, 8, and 24 hours, cells were lysed, and total RNA was obtained. A quan-
titative and semi-quantitative PCR for E1A RNA was performed using 
specific primers (Q-E1A-Fwd and Q-E1A-Rev and F-E1A-560-Fwd and 
R-E1A-1632 Rev; See Supplementary Table S1). For western blot stud-
ies, cells were transduced with the different viruses at 500 multiplicity of 
infection. Total protein extraction and western blots were performed as 
described.45 The membrane was probed with an anti-E1A antibody (M73; 
Santa Cruz Biotechnology, Santa Cruz, CA), and an anti-β-actin antibody 
(A4700; Sigma, St Louis, MO) was used as a loading control. To analyze 
the β-catenin protein in the GIC cell lines, nuclear extracts were prepared 
as previously reported.46 Protein levels were quantified by the Bradford 
assay using bovine serum albumin as a standard. Primary antibodies used 
included β- catenin (sc-1496; Santa Cruz Biotechnology) and anti-Histone 
H3, pan, clone A3S (05-928, Millipore, Billerica MA) as an internal control.
In vivo studies. Five- to six-week-old female and male athymic N:NIH 
(S)-nude mice (obtained from the animal facility of the Faculty of 
Veterinary, Universidad de La Plata, Argentina) were s.c. injected in one 
flank with 5 × 106 SW1990 cells. Tumor volumes were estimated once a 
week from caliper measurements using the following formula: volume = 
0.52 × (width)2 × length. For orthotopic studies, mice were anesthetized 
via the i.p. injection of 80 mg/kg ketamine (Aveco, Fort Dodge, IA) and 
10 mg/kg xylazine (Rugby Laboratories, Rockville, MD). A small (1 cm) 
lateral subcostal laparotomy was performed. A total of 5 × 105 SW1990 cells 
suspended in 50 ml phosphate-buffered saline were injected beneath the 
capsule of the pancreas. Following cell injection, cell bleeding or leakage 
from the pancreas was stopped by applying Matrigel (Matrigel Basement 
Membrane Matrix, BD Biosciences, Franklin Lakes, NJ) to the site of 
injection, and the abdominal wall and skin were closed. At the end of the 
experiments (40 days post adenoviral injection), the mice were euthanized. 
Twice weekly, whole-body images of each mouse were obtained with a 
bioluminescence assay. Animals were anesthetized, and the D-Firefly-
Luciferin substrate (Xenogen, Alameda, CA) was administered intra-
peritoneally (32 mg/kg). Luciferase activity was visualized using an in 
vivo bioluminescence system (IVIS50; Xenogen) and Living Image 2.20.1 
Software. In vivo experiments were performed following the institutional 
guidelines approved by the NIH (see below), and all animals under study 
received food and water ad-libitum. In vivo experiments were approved by 
the Institutional Animal Care and Use Committee of Instituto Leloir.
Statistical analysis. Each in vitro experiment was repeated at least three 
times with three replicates. Data are shown as the means ± SD. Multiple 
group comparisons were performed with one-way analysis of variance 
using the STATISTICA 9.0 software (Statsoft Inc., Tulsa, OK). A P < 0.05 
was considered significant.
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